HER2 Overexpression
2 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors (NCT07361562) | Cogent Biosciences, Inc. | 2025-12-30 |
| A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer (NCT07035353) | Tianjin Medical University Cancer Institute and Hospital | 2025-06-30 |
Track HER2 Overexpression automatically
Every clearance here is in the API, with alerts when new ones post.